LY6G5B

Across TCGA pan-cancer cohorts, LY6G5B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LY6G5B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher LY6G5B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY6G5B expression acts as an unfavorable survival marker.

UCS, BLCA, and LIHC are the cancer types where LY6G5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
BLCA	OS	Median	All	0.117	0.720	<.001	36	view →
LIHC	OS	Median	All	0.255	0.773	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LY6G5B–UCS (DFS)

Open the UCS breakdown →